Hélène Bacquet-Deschryver

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jérôme Avouac, Élodie Drumez, É. Hachulla et al. · The Lancet Rheumatology · 2021 · 290 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +9

Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study

Damien Fouache, Vincent Goëb, Nathalie Massy‐Guillemant et al. · Lara D. Veeken · 2009 · 99 citations · Full text

Pathology, Dermatology, Psoriatic Arthritis +22

Impact of Three Anti-TNFα Biologics on Existing and Emergent Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy Patients

Hélène Bacquet-Deschryver, F. Jouen, Muriel Quillard et al. · Journal of Clinical Immunology · 2008 · 53 citations

Inflammation, Rheumatology, Rheumatoid Disorder +13

A 3mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs

Ginette Tenga, Vincent Goëb, Thierry Lequerré et al. · Joint Bone Spine · 2010 · 22 citations

Inflammation, Rheumatology, Translational Medicine +14